For both the SAD and MAD portions of the trial, pharmacodynamic markers, including pSTAT levels, were measured.

The improvement of our understanding on the pharmacokinetic and pharmacodynamic characteristics of these drugs enables the tailoring of the most appropriate anti-thrombotic therapy to the ...

LOS ALTOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: UNCY), a clinical-stage biotechnology company developing ...

Introduction: A harmonized clinical breakpoint for interpreting antimicrobial susceptibility testing of oxytetracycline in cattle is currently lacking in Europe. This ...

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting ...

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic nicotinamide ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously ...

Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...

Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and ...

Two of the eight heavily advertised supplements examined -- Relief Factor and Nugenix's Total-T and Free T products -- had no ...